logo
logo
AI + EXCLUSIVE DATA

AI identifies M&A opportunities from proprietary sources

Our AI analyzes exclusive acquisition data to predict which merged companies need YOUR integration capabilities.

10-25 M&A leads daily • Tech stack analysis • Integration scoring
Start with:
✓Flexible Plans • $39/mo or $29/mo annual
✓AI + exclusive M&A intelligence
✓Post-merger opportunity analysis
INDUSTRY FIRST

Solve Therapeutics, Inc. Acquires Cereius, Inc., A Duke University Spin-Out

Jun 22, 2023•about 2 years ago

Acquiring Company

Solve Therapeutics

Acquired Company

Duke University Spin-Out

BelmontTherapeuticsBiotechnologyHealth Care

Description

Solve Therapeutics, Inc. (SolveTx), a biopharmaceutical company developing novel antibody-based therapeutics, announces the acquisition of Cereius, Inc. (Cereius), a private company developing innovative next-generation, targeted radiodiagnostics and radiotherapeutics for cancer patients. Cereius was co-founded by Professor Michael Zalutsky and Dr. Kimberly Lynn Blackwell around technology initially developed at Duke University and further advanced by the Cereius research team.

Company Information

Company

Solve Therapeutics

Location

Belmont, California, United States

About

Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.

FundzWatch™ Score

80
High M&A Activity

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed